

Mike Paulden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2577339/publications.pdf>

Version: 2024-02-01

47
papers

1,140
citations

430442

18
h-index

395343

33
g-index

48
all docs

48
docs citations

48
times ranked

1611
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of reporting of economic evaluations in rehabilitation research: a systematic review. <i>Disability and Rehabilitation</i> , 2022, 44, 2233-2240.	0.9	5
2	Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates. <i>Pharmacoeconomics</i> , 2022, 40, 31-43.	1.7	16
3	Small differences in EQ-5D-5L health utility scores were interpreted differently between and within respondents. <i>Journal of Clinical Epidemiology</i> , 2022, 142, 133-143.	2.4	2
4	Trends in Author-Reported Cost-Effectiveness Thresholds in the United States from 1995 to 2018: Implications for Discount Rates. <i>Medical Decision Making</i> , 2022, , 0272989X2210971.	1.2	1
5	Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups. <i>Pharmacoeconomics</i> , 2022, 40, 633-645.	1.7	16
6	Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier. <i>Pharmacoeconomics</i> , 2021, 39, 19-24.	1.7	1
7	NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests. <i>Pharmacoeconomics</i> , 2021, 39, 139-146.	1.7	1
8	Noninvasive management of soft tissue disorders of the shoulder: A clinical practice guideline from the Ontario Protocol for Traffic Injury Management (OPTIMA) collaboration. <i>European Journal of Pain</i> , 2021, 25, 1644-1667.	1.4	6
9	Modifying the quality-adjusted life year calculation to account for meaningful change in health-related quality of life: insights from a pragmatic clinical trial. <i>European Journal of Health Economics</i> , 2021, 22, 1441-1451.	1.4	0
10	Economic Evaluation of Sucrose Octasulfate Dressing for the Treatment of Diabetic Foot Ulcers for Type 2 Diabetes Patients. <i>Canadian Journal of Diabetes</i> , 2021, , .	0.4	3
11	Modifying NICE's Approach to Equity Weighting. <i>Pharmacoeconomics</i> , 2021, 39, 147-160.	1.7	14
12	Impact and Cost-Effectiveness of Oncotype DX for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer. <i>gulf journal of oncology, The</i> , 2021, 1, 27-35.	0.2	0
13	Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer. <i>Pharmacogenomics Journal</i> , 2020, 20, 27-46.	0.9	22
14	One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit. <i>Pharmacoeconomics</i> , 2020, 38, 135-141.	1.7	32
15	Implementing Interventions with Varying Marginal Cost-Effectiveness: An Application in Precision Medicine. <i>Medical Decision Making</i> , 2020, 40, 924-938.	1.2	8
16	Calculating and Interpreting ICERs and Net Benefit. <i>Pharmacoeconomics</i> , 2020, 38, 785-807.	1.7	59
17	Why it's Time to Abandon the ICER. <i>Pharmacoeconomics</i> , 2020, 38, 781-784.	1.7	31
18	The health and financial impacts of a sugary drink tax across different income groups in Canada. <i>Economics and Human Biology</i> , 2020, 38, 100869.	0.7	12

#	ARTICLE	IF	CITATIONS
19	The Joint Committee on Vaccination and Immunisation's Advice on Extending Human Papillomavirus Vaccination to Boys: Were Cost-Effectiveness Analysis Guidelines Bent to Achieve a Politically Acceptable Decision?. <i>Value in Health</i> , 2019, 22, 1227-1230.	0.1	5
20	Non-pharmacological management of persistent headaches associated with neck pain: A clinical practice guideline from the Ontario protocol for traffic injury management (OPTIMA) collaboration. <i>European Journal of Pain</i> , 2019, 23, 1051-1070.	1.4	61
21	Implications of Nonmarginal Budgetary Impacts in Health Technology Assessment: A Conceptual Model. <i>Value in Health</i> , 2019, 22, 891-897.	0.1	7
22	Appraising the cost-effectiveness of vaccines in the UK: Insights from the Department of Health Consultation on the revision of methods guidelines. <i>Vaccine</i> , 2019, 37, 2831-2837.	1.7	4
23	Accounting for Timing when Assessing Health-Related Policies. <i>Journal of Benefit-Cost Analysis</i> , 2019, 10, 73-105.	0.6	17
24	Incorporating equity in economic evaluations: a multi-attribute equity state approach. <i>European Journal of Health Economics</i> , 2018, 19, 489-498.	1.4	26
25	Turning High-Risk Individuals: An Economic Evaluation of Repositioning Frequency in Long-Term Care. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1409-1414.	1.3	1
26	Non-invasive Prenatal Testing and the Unveiling of an Impaired Translation Process. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 10-17.	0.3	19
27	Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine. <i>Pharmacoeconomics</i> , 2017, 35, 5-13.	1.7	22
28	A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models. <i>Pharmacoeconomics</i> , 2017, 35, 817-830.	1.7	22
29	Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 239-242.	0.7	62
30	Determinants of Change in the Cost-effectiveness Threshold. <i>Medical Decision Making</i> , 2017, 37, 264-276.	1.2	38
31	Pitfalls of prioritizing cost-effectiveness in the assessment of medical innovation: A comment on Wallis and Detsky guest editorial. <i>Canadian Urological Association Journal</i> , 2017, 12, E163-5.	0.3	0
32	Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online. <i>BMC Cancer</i> , 2017, 17, 685.	1.1	14
33	A probabilistic threshold analysis of metformin (Met) with enzalutamide (Enza) to determine the cost and added efficacy needed to make such a combination therapy cost-effective (CE).. <i>Journal of Clinical Oncology</i> , 2017, 35, e577-e577.	0.8	0
34	Which interventions are cost-effective for the management of whiplash-associated and neck pain-associated disorders? A systematic review of the health economic literature by the Ontario Protocol for Traffic Injury Management (OPTIMA) Collaboration. <i>Spine Journal</i> , 2016, 16, 1582-1597.	0.6	29
35	Management of neck pain and associated disorders: A clinical practice guideline from the Ontario Protocol for Traffic Injury Management (OPTIMA) Collaboration. <i>European Spine Journal</i> , 2016, 25, 2000-2022.	1.0	173
36	Cancer Drugs Fund 2.0: A Missed Opportunity?. <i>Pharmacoeconomics</i> , 2016, 34, 629-633.	1.7	10

#	ARTICLE	IF	CITATIONS
37	Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment. <i>Medical Decision Making</i> , 2016, 36, 375-390.	1.2	6
38	Life at a Premium: Considering an End-of-Life Premium in Value-Based Reimbursement. , 2016, , 123-139.		2
39	Metformin (Met): A cost-effective adjunct therapy with enzalutamide (Enza) for metastatic castrate-resistant prostate cancer (mCRPC)?. <i>Journal of Clinical Oncology</i> , 2016, 34, 340-340.	0.8	0
40	Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework. <i>Pharmacoeconomics</i> , 2015, 33, 255-269.	1.7	77
41	Objectivity and Equity: Clarity Required. A Response to Hill and Olson. <i>Pharmacoeconomics</i> , 2014, 32, 1249-1250.	1.7	1
42	Some Inconsistencies in NICE's Consideration of Social Values. <i>Pharmacoeconomics</i> , 2014, 32, 1043-1053.	1.7	43
43	NICE's Selective Application of Differential Discounting: Ambiguous, Inconsistent, and Unjustified. <i>Value in Health</i> , 2014, 17, 493-496.	0.1	34
44	Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?. <i>Pharmacoeconomics</i> , 2014, 32, 315-318.	1.7	10
45	Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer. <i>Value in Health</i> , 2013, 16, 729-739.	0.1	36
46	Budget allocation and the revealed social rate of time preference for health. <i>Health Economics (United Kingdom)</i> , 2012, 21, 612-618.	0.8	32
47	Discounting and decision making in the economic evaluation of health-care technologies. <i>Health Economics (United Kingdom)</i> , 2011, 20, 2-15.	0.8	156